283 related articles for article (PubMed ID: 28415597)
1. Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
Roseweir AK; McCall P; Scott A; Liew B; Lim Z; Mallon EA; Edwards J
Oncotarget; 2017 Jun; 8(23):37172-37185. PubMed ID: 28415597
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
3. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
4. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
[TBL] [Abstract][Full Text] [Related]
7. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins.
Merlin JL; Harlé A; Lion M; Ramacci C; Leroux A
Oncol Rep; 2013 Oct; 30(4):1943-8. PubMed ID: 23900300
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer.
Lyalkin SA; Verevkina NO; Alekseyenko OO; Syvak LA
Exp Oncol; 2020 Jun; 42(2):140-143. PubMed ID: 32602289
[TBL] [Abstract][Full Text] [Related]
10. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
[TBL] [Abstract][Full Text] [Related]
11. Expression of androgen receptor in invasive ductal breast carcinomas: a clinicopathological study from Jordan.
Obeidat FN; Ahram M; Al-Khader A; Mbaideen SA; Hassan H; Altarawneh B; Battah K
Ann Saudi Med; 2018; 38(5):326-335. PubMed ID: 30284987
[TBL] [Abstract][Full Text] [Related]
12. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters.
Teoh PY; Tan GC; Mahsin H; Wong YP
Malays J Pathol; 2019 Aug; 41(2):125-132. PubMed ID: 31427547
[TBL] [Abstract][Full Text] [Related]
14. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
15. The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
McNamara KM; Oguro S; Omata F; Kikuchi K; Guestini F; Suzuki K; Yang Y; Abe E; Hirakawa H; Brown KA; Takanori I; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2017 Jan; 161(2):213-227. PubMed ID: 27848152
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
[TBL] [Abstract][Full Text] [Related]
18. Expression of androgen receptor and its phosphorylated forms in breast cancer progression.
Ren Q; Zhang L; Ruoff R; Ha S; Wang J; Jain S; Reuter V; Gerald W; Giri DD; Melamed J; Garabedian MJ; Lee P; Logan SK
Cancer; 2013 Jul; 119(14):2532-40. PubMed ID: 23605249
[TBL] [Abstract][Full Text] [Related]
19. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
20. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
